REFERENCES
1. DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. Coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381:2043-50.
2. Baxter M, Ahmad T, Colville A, Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis. 2015;61:136-7.
3. Cymbal M, Chatterjee A, Baggott B. Fecal microbiota transplantation: current evidence and future directions. Cleve Clin J Med. 2025;92:421-8.
4. Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a Phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82:1527-38.
5. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection. N Engl J Med. 2022;386:220-9.
6. Bethlehem L, Bartu L, Marke G, et al. 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial. Nat Med. 2026;32:2546-55.
7. Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595-602.
8. Kootte RS, Levin E, Salojärvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611-619.e6.
9. Zhang F, Zuo T, Wan Y, et al. Multi-omic analyses identify mucosa bacteria and fecal metabolites associated with weight loss after fecal microbiota transplantation. Innovation (Camb). 2022;3:100304.
10. Zhang J, Zhu G, Wan L, et al. Effect of fecal microbiota transplantation in children with autism spectrum disorder: a systematic review. Front Psychiatry. 2023;14:1123658.
11. Leong KSW, Jayasinghe TN, Wilson BC, et al. Effects of fecal microbiome transfer in adolescents with obesity: the gut bugs randomized controlled trial. JAMA Netw Open. 2020;3:e2030415.
12. Recasens-Alvarez C, Heap G, Green G. The evolution of the obesity drug market. Nat Rev Drug Discov. 2025;24:902-3.
13. DeLeon O, Mocanu M, Tan A, et al. Microbiome mismatches from microbiota transplants lead to persistent off-target metabolic and immunomodulatory effects. Cell. 2025;188:3927-3941.e13.
14. Shalon D, Culver RN, Grembi JA, et al. Profiling the human intestinal environment under physiological conditions. Nature. 2023;617:581-91.
15. She JJ, Liu WX, Ding XM, et al. Defining the biogeographical map and potential bacterial translocation of microbiome in human ‘surface organs’. Nat Commun. 2024;15:427.
16. Mullish BH, Roberts LA, Williams HRT. Microbiota transplants: the concept of 'microbiome mismatching' explored. Signal Transduct Target Ther. 2025;10:374.
18. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214.
19. Feng J, Liu X, Zhu H, et al. Early diabetes-like phenotypes in germ-free mice induced by gut microbiota from patients with type 2 diabetes. Animal Model Exp Med. 2026;9:1202-16.
20. Lefebvre P, Lalloyer F, Baugé E, et al. Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin. JCI Insight. 2017;2:92264.
21. Mi F, Guo J, Zheng W, Shen J, Ye H. Fecal microbiota transplantation alleviates steatosis and inflammation in high-fat and high-sugar diet-induced fatty liver in mice. Front Cell Dev Biol. 2026;14:1723128.
22. Wang H, Liu H, Wang M, et al. Integrated proteomics and metabolomics reveal the direct hepatic protection of propionate against alcoholic liver disease via the RGN-PPARα Pathway. Nutrients. 2026;18:872.
23. Yang G, Jena PK, Hu Y, et al. The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study. Biomark Res. 2023;11:20.
24. Psichas A, Sleeth ML, Murphy KG, et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond). 2015;39:424-9.
25. Perino A, Velázquez-Villegas LA, Bresciani N, et al. Central anorexigenic actions of bile acids are mediated by TGR5. Nat Metab. 2021;3:595-603.
26. Kuhre RE, Wewer Albrechtsen NJ, Larsen O, et al. Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Mol Metab. 2018;11:84-95.
27. Chambers ES, Byrne CS, Morrison DJ, et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut. 2019;68:1430-8.
28. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650-4.
29. Rangwala SM, D'Aquino K, Zhang YM, et al. A long-acting PYY(3-36) analog mediates robust anorectic efficacy with minimal emesis in nonhuman primates. Cell Metab. 2019;29:837-843.e5.
30. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69-72.
31. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-30.
32. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis. 2015;2:ofv004.
33. Paramsothy S, Nielsen S, Kamm MA, et al. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology. 2019;156:1440-1454.e2.
34. Martinez-Gili L, McDonald JAK, Liu Z, et al. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. Gut Microbes. 2020;12:1810531.
35. Chen Y, Zhiliang L, Jiaqu C, et al. Fecal microbiota and human intestinal fluid transplantation: methodologies and outlook. Front Med (Lausanne). 2022;9:830004.
36. Pastor B, Shkoporov AN, Hill C. Not just passengers: phages as agents of genetic exchange in fecal microbiota transplantation. Cell Host Microbe. 2026;34:780-9.
37. Draper LA, Ryan FJ, Smith MK, et al. Long-term colonisation with donor bacteriophages following successful faecal microbial transplantation. Microbiome. 2018;6:220.
